DiaSorin S.p.A. (DSRLF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
DiaSorin S.p.A. (DSRLF) with AI Score 52/100 (Hold). DiaSorin S. p. A. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026DiaSorin S.p.A. (DSRLF) Healthcare & Pipeline Overview
DiaSorin S.p.A., founded in 1968, is a global leader in immunodiagnostics and molecular diagnostics, offering a broad portfolio of testing kits and platforms. With a focus on infectious diseases and specialty diagnostics, DiaSorin serves diverse markets across Europe, the Americas, Asia Pacific, and China, maintaining a strong competitive position through strategic partnerships and innovative solutions.
Investment Thesis
DiaSorin S.p.A. presents a notable research candidate within the diagnostics sector, supported by its strong market position, diversified product portfolio, and global reach. The company's focus on specialty diagnostics and infectious disease testing positions it favorably to capitalize on growing demand for advanced diagnostic solutions. With a P/E ratio of 18.19 and a profit margin of 15.8%, DiaSorin demonstrates solid profitability. Key growth catalysts include the expansion of its LIAISON platform, strategic partnerships, and entry into new geographic markets. However, investors may want to evaluate potential risks such as competition, regulatory changes, and fluctuations in currency exchange rates. The company's beta of 0.62 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $4.38 billion, reflecting its significant presence in the diagnostics market.
- P/E ratio of 18.19, indicating a potentially reasonable valuation relative to its earnings.
- Profit margin of 15.8%, demonstrating efficient operations and profitability.
- Gross margin of 65.7%, showcasing the company's ability to maintain strong pricing power and cost control.
- Dividend yield of 1.86%, providing a steady income stream for investors.
Competitors & Peers
Strengths
- Strong market position in immunodiagnostics and molecular diagnostics.
- Diversified product portfolio with a broad range of diagnostic tests.
- Global presence with direct operations in key markets.
- Proprietary LIAISON technology platform.
Weaknesses
- Reliance on a limited number of key products.
- Exposure to regulatory risks and changes in healthcare policies.
- Competition from larger, more diversified players.
- Dependence on third-party suppliers for certain raw materials and components.
Catalysts
- Upcoming: Launch of new diagnostic tests for emerging infectious diseases in Q3 2026.
- Ongoing: Expansion of the LIAISON platform with new assays for autoimmune disorders.
- Ongoing: Strategic partnerships to expand product portfolio and geographic reach.
- Ongoing: Geographic expansion into emerging markets in Asia Pacific and Latin America.
Risks
- Potential: Intense competition from established players and new entrants in the diagnostics market.
- Potential: Price pressures from healthcare providers and payers.
- Potential: Technological obsolescence and the need for continuous innovation.
- Ongoing: Regulatory risks and changes in healthcare policies.
- Ongoing: Dependence on third-party suppliers for certain raw materials and components.
Growth Opportunities
- Expansion of LIAISON Platform: DiaSorin can further expand its LIAISON platform by developing and launching new assays for emerging infectious diseases and specialty diagnostic areas. This includes assays for autoimmune disorders, bone and mineral metabolism, and gastrointestinal diseases. The global market for autoimmune disease diagnostics is projected to reach $12.7 billion by 2027, presenting a significant opportunity for DiaSorin to capture market share. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: DiaSorin can pursue strategic partnerships and acquisitions to expand its product portfolio, geographic reach, and technological capabilities. Collaborations with companies specializing in molecular diagnostics, point-of-care testing, or digital health solutions can enhance DiaSorin's competitive position and accelerate its growth. The company's existing partnerships with QIAGEN, TTP, and MeMed demonstrate its commitment to strategic collaborations. Timeline: Ongoing.
- Geographic Expansion: DiaSorin has opportunities to expand its presence in emerging markets, particularly in Asia Pacific and Latin America, where demand for diagnostic testing is growing rapidly. Establishing local manufacturing facilities, distribution networks, and sales teams in these regions can enable DiaSorin to better serve local customers and capitalize on growth opportunities. The Asia Pacific IVD market is projected to be the fastest-growing region, driven by increasing healthcare expenditure and rising awareness of diagnostic testing. Timeline: 2026-2028.
- Development of Point-of-Care Testing Solutions: DiaSorin can invest in the development of point-of-care testing (POCT) solutions that enable rapid and convenient diagnostic testing at the point of care, such as in physician's offices, emergency rooms, and pharmacies. POCT solutions can improve patient outcomes by enabling faster diagnosis and treatment decisions. The global POCT market is projected to reach $40 billion by 2028, driven by increasing demand for decentralized testing and technological advancements. Timeline: 2027-2030.
- Digital Health Integration: DiaSorin can integrate its diagnostic solutions with digital health platforms and data analytics tools to provide clinicians with comprehensive insights and decision support. This includes developing mobile apps, cloud-based platforms, and data analytics algorithms that can analyze patient data, identify trends, and personalize treatment plans. The integration of digital health technologies can improve patient engagement, enhance clinical efficiency, and drive better healthcare outcomes. Timeline: 2028-2030.
Opportunities
- Expansion into emerging markets with high growth potential.
- Development of new diagnostic tests for emerging infectious diseases.
- Strategic partnerships and acquisitions to expand product portfolio and geographic reach.
- Integration of digital health technologies to enhance diagnostic solutions.
Threats
- Intense competition from established players and new entrants.
- Price pressures from healthcare providers and payers.
- Technological obsolescence and the need for continuous innovation.
- Economic downturns and their impact on healthcare spending.
Competitive Advantages
- Proprietary LIAISON technology platform.
- Extensive portfolio of diagnostic tests.
- Global distribution network.
- Strong brand reputation in the diagnostics market.
About DSRLF
DiaSorin S.p.A., established in 1968 and headquartered in Saluggia, Italy, is a global biotechnology company specializing in the development, production, and distribution of in-vitro diagnostics (IVD). The company operates in the immunodiagnostics and molecular diagnostics segments, providing a wide array of testing kits and platforms used in clinical laboratories worldwide. DiaSorin's product portfolio includes the LIAISON series of immunodiagnostic platforms (LIAISON XS, LIAISON XL, and LIAISON XL LAS) and the LIAISON MDX molecular diagnostics platform. These platforms are designed for the automated analysis of biological samples to detect and quantify various analytes, aiding in the diagnosis and monitoring of diseases. The company's tests cover a range of clinical areas, including infectious diseases, bone and mineral metabolism, hepatitis, retrovirus, and autoimmune disorders. DiaSorin has expanded its global presence through strategic partnerships and acquisitions, establishing a direct presence in key markets such as Europe, North America, and Asia. The company's commitment to innovation is reflected in its ongoing research and development efforts, aimed at expanding its product offerings and improving the performance of its diagnostic solutions. DiaSorin's business model focuses on providing high-value diagnostic solutions to clinical laboratories, hospitals, and research institutions, contributing to improved patient outcomes and healthcare efficiency.
What They Do
- Develops and manufactures immunodiagnostic testing kits.
- Produces molecular diagnostic testing kits.
- Distributes diagnostic products globally.
- Offers LIAISON XS, LIAISON XL, and LIAISON XL LAS immunodiagnostic platforms.
- Provides the LIAISON MDX molecular diagnostics platform.
- Partners with other companies for diagnostic solutions.
Business Model
- Develops and manufactures in-vitro diagnostic (IVD) kits and platforms.
- Sells diagnostic products to clinical laboratories, hospitals, and research institutions.
- Generates revenue through direct sales and distribution agreements.
- Invests in research and development to expand its product portfolio and improve its diagnostic solutions.
Industry Context
DiaSorin operates within the global in-vitro diagnostics (IVD) market, which is characterized by continuous innovation and increasing demand for accurate and rapid diagnostic testing. The market is driven by factors such as the aging population, rising prevalence of chronic diseases, and technological advancements in diagnostic techniques. The competitive landscape includes major players such as CNVVF (Siemens Healthineers), CNVVY (Roche Holding AG), and FLMNF (Thermo Fisher Scientific), each offering a broad range of diagnostic solutions. DiaSorin differentiates itself through its focus on specialty diagnostics and its LIAISON platform, which offers a comprehensive menu of tests on a single instrument.
Key Customers
- Clinical laboratories
- Hospitals
- Research institutions
- Diagnostic centers
Financials
Chart & Info
DiaSorin S.p.A. (DSRLF) stock price: Price data unavailable
Latest News
No recent news available for DSRLF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DSRLF.
Price Targets
Wall Street price target analysis for DSRLF.
MoonshotScore
What does this score mean?
The MoonshotScore rates DSRLF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Carlo Rosa
Chief Executive Officer
Carlo Rosa serves as the Chief Executive Officer of DiaSorin S.p.A., bringing extensive experience in the diagnostics and healthcare industries. His career spans various leadership roles, including positions at multinational corporations focused on medical devices and biotechnology. He has a strong background in strategic planning, business development, and operational management. Mr. Rosa's expertise lies in driving growth through innovation, market expansion, and strategic partnerships. His leadership is focused on strengthening DiaSorin's position as a global leader in the diagnostics sector.
Track Record: Under Carlo Rosa's leadership, DiaSorin has achieved significant milestones, including the expansion of its LIAISON platform and the successful launch of new diagnostic tests. He has overseen strategic acquisitions and partnerships that have strengthened the company's competitive position and expanded its geographic reach. His focus on innovation and operational excellence has contributed to DiaSorin's consistent financial performance and growth.
DSRLF OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market, indicating that DiaSorin S.p.A. (DSRLF) may have limited regulatory oversight and reporting requirements compared to companies listed on major exchanges like the NYSE or NASDAQ. Companies in this tier may not meet the minimum financial standards or disclosure requirements for higher tiers, potentially increasing investment risks. Investors should be aware that information availability and transparency may be limited.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight and reporting requirements.
- Potential for lower liquidity and wider bid-ask spreads.
- Increased risk of price volatility and manipulation.
- Limited availability of financial information and transparency.
- Higher risk of fraud or misrepresentation.
- Verify the company's financial information and reporting practices.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or investigations against the company.
- Established business operations with a history of revenue generation.
- Presence of a qualified management team with relevant experience.
- Positive reviews or ratings from independent analysts or rating agencies.
- Compliance with applicable laws and regulations.
- Audited financial statements and transparent reporting practices.
What Investors Ask About DiaSorin S.p.A. (DSRLF)
What does DiaSorin S.p.A. do?
DiaSorin S.p.A. specializes in the development, manufacturing, and distribution of in-vitro diagnostics (IVD) used in clinical laboratories worldwide. The company operates through two main segments: immunodiagnostics and molecular diagnostics. Its product portfolio includes the LIAISON series of immunodiagnostic platforms and the LIAISON MDX molecular diagnostics platform. These platforms are used to detect and quantify various analytes in biological samples, aiding in the diagnosis and monitoring of diseases such as infectious diseases, bone and mineral metabolism disorders, and autoimmune conditions. DiaSorin serves a global customer base, including clinical laboratories, hospitals, and research institutions.
What do analysts say about DSRLF stock?
Analyst coverage of DSRLF stock is limited due to its OTC listing. However, key valuation metrics such as the P/E ratio of 18.19 and the profit margin of 15.8% provide insights into the company's financial performance. Growth considerations include the expansion of its LIAISON platform, strategic partnerships, and entry into new geographic markets. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks before making any investment decisions. Analyst consensus is Unknown.
What are the main risks for DSRLF?
DiaSorin S.p.A. faces several risks, including intense competition from established players and new entrants in the diagnostics market. Price pressures from healthcare providers and payers can also impact the company's profitability. Technological obsolescence and the need for continuous innovation pose a challenge, requiring ongoing investments in research and development. Regulatory risks and changes in healthcare policies can affect the company's operations and financial performance. Additionally, DiaSorin is dependent on third-party suppliers for certain raw materials and components, which could disrupt its supply chain.
What are the key factors to evaluate for DSRLF?
DiaSorin S.p.A. (DSRLF) currently holds an AI score of 52/100, indicating moderate score. Key strength: Strong market position in immunodiagnostics and molecular diagnostics.. Primary risk to monitor: Potential: Intense competition from established players and new entrants in the diagnostics market.. This is not financial advice.
How frequently does DSRLF data refresh on this page?
DSRLF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven DSRLF's recent stock price performance?
Recent price movement in DiaSorin S.p.A. (DSRLF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong market position in immunodiagnostics and molecular diagnostics.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider DSRLF overvalued or undervalued right now?
Determining whether DiaSorin S.p.A. (DSRLF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying DSRLF?
Before investing in DiaSorin S.p.A. (DSRLF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- AI analysis pending, which could provide additional insights.